[{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Erlotinib","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HS-130","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Elusys Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Heat Biologics \/ Heat Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Heat Biologics \/ Heat Biologics"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Elusys Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Heat Biologics \/ Heat Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Heat Biologics \/ Heat Biologics"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PTX-35","moa":"Tumor necrosis factor receptor member 25 (TNFRSF25)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PTX-35","moa":"Tumor necrosis factor receptor member 25 (TNFRSF25)","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PTX-35","moa":"Tumor necrosis factor receptor member 25 (TNFRSF25)","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"gp-96 Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heat Biologics \/ Heat Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Heat Biologics"}]

Find Clinical Drug Pipeline Developments & Deals by Heat Biologics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Pursuant to this acquisition, NightHawk announced it plans to migrate manufacturing of ANTHIM® to its planned Scorpion biomanufacturing facility in Manhattan, Kansas, which is being constructed to support development of commercial-scale biologics and la...

                          Product Name : Anthim

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 20, 2022

                          Lead Product(s) : Obiltoxaximab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Elusys Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular products.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 25, 2022

                          Lead Product(s) : Viagenpumatucel-l,Erlotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The strategic acquisition of Elusys is intended to enhance Heat’s immunotherapy portfolio and further position Heat to take a lead role in the biodefense space. The addition of ANTHIM (obiltoxaximab) Injection, together with Heat’s previously announc...

                          Product Name : Anthim

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          December 21, 2021

                          Lead Product(s) : Obiltoxaximab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Elusys Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 11, 2021

                          Lead Product(s) : PTX-35

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Heat Biologics continue to make good progress on its clinical-stage portfolio, as well as its COVID-19 vaccine platform, and look forward to presenting additional HS-110 data on May 29 at ASCO.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          November 05, 2020

                          Lead Product(s) : Viagenpumatucel-l,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Preclinical studies have demonstrated PTX-35, in combination with antigen-driven immunotherapies, resulted in enhanced anti-tumor properties, including potent proliferation of antigen-specific T cells, production of effector cytokines and augmented effec...

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 06, 2020

                          Lead Product(s) : PTX-35

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The patent covers compositions of matter that are part of Heat's gp96 platform (antigen presentation, T cell activation, TLR activation) in combination with Inducible T cell Co-stimulator (ICOS) ligand or ICOSL, a T cell immune booster, in a single thera...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 10, 2020

                          Lead Product(s) : COVID-19 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : First patient has been treated in the Company's first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate developed by Heat Biologics' Pelican Therapeutics subsidiary.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 22, 2020

                          Lead Product(s) : PTX-35

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Median overall survival (OS) of 28.7 months for HS-110 in combination with nivolumab in previously treated checkpoint inhibitor naïve non-small cell lung cancer (NSCLC) patients.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          May 14, 2020

                          Lead Product(s) : Viagenpumatucel-l,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Heat's COVID-19 vaccine is designed to drive T cell immunity, while also activating antibody responses and innate immunity, which may complement conventional COVID-19 vaccines in combination approaches by enhancing T cell immunity.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 08, 2020

                          Lead Product(s) : COVID-19 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank